A review of current and emerging therapeutic strategies in multiple sclerosis

American Journal of Managed Care

Volumn 19, Issue 2 SUPPL, 2013, Pages

  Tullman, Mark J ^a  

^a MISSOURI BAPTIST MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; BACLOFEN; BETA INTERFERON; DIAZEPAM; GABAPENTIN; GLATIRAMER; GLUCOSE; METHYLPREDNISOLONE; MODAFINIL; OPIATE; PREDNISONE;

ASEPTIC NECROSIS; BEHAVIOR DISORDER; CLINICAL FEATURE; DISEASE EXACERBATION; DRUG MEGADOSE; GLUCOSE BLOOD LEVEL; HUMAN; INFECTION; INSOMNIA; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SYSTEMIC THERAPY; PATHOPHYSIOLOGY;

HUMANS; MULTIPLE SCLEROSIS;

EID: 84891645279     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Berger JR. Functional improvement and symptom management in multiple sclerosis: clinical efficacy of current therapies. Am J Manag Care. 2011;17(suppl 5):S146-S153.
2. Kes VB, Zavoreo I, Serić V, et al Croatian Society for Neurovascular Disorders of Croatian Medical Association; Croatian Society of Neurology of Croatian Medical Association; Referral Center for Demyelinating Diseases of the CNS. Recommendations for diagnosis and management of multiple sclerosis. Acta Clin Croat. 2012;51(1):117-135.
3. Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011;17(suppl 5): S139-S145.
4. Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler. 2007;13(3):357-368. (Pubitemid 46705997)
5. Goodman AD, Brown TR, Krupp LB, et al; Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373(9665):732-738.
6. Cornblath DR, Bienen EJ, Blight AR. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials. Clin Ther. 2012;34(5):1056-1069.
7. Miravalle AA. Guidelines and best practices for appropriate use of dalfampridine in managed care populations. Am J Manag Care. 2011;17(suppl 5):S154-S160.
8. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008;7(12):1139-1151.
9. Kim E, Cameron M, Lovera J, Schaben L, Bourdette D, Whitham R. American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study. Mult Scler. 2011;17(12):1523-1526.
10. Torkildsen Ø, Wergeland S, Bakke S, et al. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, doubleblind, placebo-controlled trial. Arch Neurol. 2012;69(8):1044-1051.
11. Stein MS, Liu Y, Gray OM, et al. A randomized trial of highdose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology. 2011;77(17):1611-1618.
12. Stoll SS, Nieves C, Tabby DS, Schwartzman R. Use of therapies other than disease-modifying agents, including complementary and alternative medicine, by patients with multiple sclerosis: a survey study. J Am Osteopath Assoc. 2012;112(1):22-28.
13. Perumal J, Khan O. Emerging disease-modifying therapies in multiple sclerosis. Curr Treat Opt Neurol. 2012;14(3):256-263.
14. Castro-Borrero W, Graves D, Frohman TC, et al. Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord. 2012;5(4):205-220.
15. Gold R. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs. 2011;25(1):37-52.
16. Comi G, Filippi M, Barkhof F, et al Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357(9268):1576-1582. (Pubitemid 32488815)
17. Kappos L, Freedman MS, Polman CH, et al BENEFIT Study Group. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389-397. (Pubitemid 47189673)
18. Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012;11(1):33-41.
19. Jacobs LD, Cookfair DL, Rudick RA, et al; the Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39(3):285-294. (Pubitemid 26100751)
20. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-1504.
21. Li DKB, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Ann Neurol. 1999;46(2):197-206. (Pubitemid 29382876)
22. De Stefano N, Sormani MP, Stubinski B, et al. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study. J Neurolog Sci. 2012;312(1-2):97-101.
23. Durelli L, Verdun E, Barbero P, et al Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359(9316):1453-1460. (Pubitemid 34457761)
24. Panitch H, Goodin DS, Francis G, et al EVIDENCE Study Group. EVidence of Interferon Dose-response: European North American Comparative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology. 2002;59(10):1496- 1506.
25. Zintaras E, Doxani C, Mprotsis T, Schmid CH, Hadjigeorgiou GM. Network analysis of randomized controlled trials in multiple sclerosis. Clin Ther. 2012;34(4):857-869.e9.
26. Johnson KP, Brooks BR, Ford CC, et al. Glatiramer acetate (Copaxone): a comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler. 2003; 9(6):585-591. (Pubitemid 37479407)
27. Comi G, Martinelli V, Rodegher M, et al; PreCISe study group. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9700):1503-1511.
28. Martinelli Boneschi FM, Rovaris M, Johnson KP, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three doubleblind, randomized, placebo-controlled clinical trials. Mult Scler. 2003;9(4): 349-355. (Pubitemid 36958017)
29. Mikol DD, Barkhof F, Chang P, et al; REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903-914.
30. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009;72(23):1976- 1983.
31. O'Connor P, Filippi M, Aranson B, et al. 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsingremitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10):889-897.
32. Calabrese M, Bernardi V, Atzori M, et al. Effect of diseasemodifying drugs on cortical lesions and atrophy in relapsingremitting multiple sclerosis. Mult Scler. 2012;18(4):418- 424.
33. Kappos L, Antel J, Comi G, et al; FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124-1140. (Pubitemid 44394919)
34. Kappos L, Radue EW, O'Connor P, et al FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
35. Cohen JA, Barkhof F, Comi G, et al TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402-415.
36. Khatri B, Barkhof F, Comi G, et al TRANSFORMS Study Group. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011;10(6):520-529.
37. Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, Tyas DA. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod. Curr Med Res Opin. 2012;28(5):767-780.
38. Gilenya [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; 2012.
39. Polman CH, O'Connor PW, Havrdova E, et al AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9): 889-910.
40. Miller DH, Khan OA, Sheremata WA, et al International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348(1):15-23. (Pubitemid 36026342)
41. Tysabri [prescribing information]. Cambridge, MA: Biogen Idec Inc; 2012.
42. Novantrone [prescribing information]. Rockland, MD: EMD Serono Inc; 2008.
43. Hartung HP, Gonsette R, König N, et al Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, doubleblind, randomised, multicentre trial. Lancet. 2002;360(9350):2018-2025. (Pubitemid 36026580)
44. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880.
45. O'Connor P, Wolinsky JS, Confavreux C, et al TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293- 1303.
46. A Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis. [TOWER]. Clinicaltrials.gov website. http://clinicaltrials. gov/show/NCT00751881. Accessed January 18, 2013.
47. Aubagio [prescribing information]. Cambridge, MA: Genzyme Corporation; 2012.